SMS Lifesciences India Past Earnings Performance
Past criteria checks 5/6
SMS Lifesciences India has been growing earnings at an average annual rate of 0.3%, while the Pharmaceuticals industry saw earnings growing at 13.5% annually. Revenues have been growing at an average rate of 2.5% per year. SMS Lifesciences India's return on equity is 10.3%, and it has net margins of 6.9%.
Key information
0.3%
Earnings growth rate
0.3%
EPS growth rate
| Pharmaceuticals Industry Growth | 17.5% |
| Revenue growth rate | 2.5% |
| Return on equity | 10.3% |
| Net Margin | 6.9% |
| Last Earnings Update | 30 Sep 2024 |
Recent past performance updates
Recent updates
Earnings Working Against SMS Lifesciences India Limited's (NSE:SMSLIFE) Share Price Following 25% Dive
Nov 14
Improved Earnings Required Before SMS Lifesciences India Limited (NSE:SMSLIFE) Stock's 58% Jump Looks Justified
Aug 27Is SMS Lifesciences India (NSE:SMSLIFE) Using Too Much Debt?
Aug 01SMS Lifesciences India Limited (NSE:SMSLIFE) Stock Catapults 27% Though Its Price And Business Still Lag The Market
Jun 13SMS Lifesciences India (NSE:SMSLIFE) Use Of Debt Could Be Considered Risky
Feb 10There's Reason For Concern Over SMS Lifesciences India Limited's (NSE:SMSLIFE) Massive 30% Price Jump
Jan 05Should Shareholders Reconsider SMS Lifesciences India Limited's (NSE:SMSLIFE) CEO Compensation Package?
Sep 23SMS Lifesciences India (NSE:SMSLIFE) Is Paying Out A Dividend Of ₹1.50
Sep 07SMS Lifesciences India (NSE:SMSLIFE) Has Affirmed Its Dividend Of ₹1.50
Aug 24SMS Lifesciences India (NSE:SMSLIFE) Will Pay A Dividend Of ₹1.50
Sep 16SMS Lifesciences India (NSE:SMSLIFE) Will Pay A Dividend Of ₹1.50
Sep 02SMS Lifesciences India (NSE:SMSLIFE) Takes On Some Risk With Its Use Of Debt
Jun 03With EPS Growth And More, SMS Lifesciences India (NSE:SMSLIFE) Is Interesting
May 13SMS Lifesciences India's (NSE:SMSLIFE) Solid Profits Have Weak Fundamentals
Nov 23Is Now The Time To Put SMS Lifesciences India (NSE:SMSLIFE) On Your Watchlist?
Jun 21Is SMS Lifesciences India (NSE:SMSLIFE) Using Too Much Debt?
Feb 22SMS Lifesciences India Limited's (NSE:SMSLIFE) Stock Has Shown Weakness Lately But Financial Prospects Look Decent: Is The Market Wrong?
Jan 04Insider Buying: The SMS Lifesciences India Limited (NSE:SMSLIFE) MD & Executive Director Just Bought 19% More Shares
Nov 27Does SMS Lifesciences India (NSE:SMSLIFE) Have A Healthy Balance Sheet?
Nov 24Revenue & Expenses Breakdown
How SMS Lifesciences India makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Sep 24 | 3,169 | 219 | 528 | 0 |
| 30 Jun 24 | 3,239 | 179 | 512 | 0 |
| 31 Mar 24 | 3,060 | 91 | 497 | 0 |
| 31 Dec 23 | 2,797 | 49 | 486 | 0 |
| 30 Sep 23 | 3,121 | 46 | 475 | 0 |
| 30 Jun 23 | 3,079 | 67 | 448 | 0 |
| 31 Mar 23 | 3,156 | 115 | 440 | 0 |
| 31 Dec 22 | 3,475 | 189 | 427 | 0 |
| 30 Sep 22 | 3,505 | 172 | 421 | 0 |
| 30 Jun 22 | 3,558 | 247 | 414 | 0 |
| 31 Mar 22 | 3,501 | 253 | 401 | 0 |
| 31 Dec 21 | 3,366 | 213 | 381 | 0 |
| 30 Sep 21 | 3,118 | 216 | 351 | 0 |
| 30 Jun 21 | 2,871 | 147 | 334 | 0 |
| 31 Mar 21 | 2,656 | 136 | 308 | 0 |
| 31 Dec 20 | 2,291 | 106 | 290 | 0 |
| 30 Sep 20 | 2,091 | 76 | 271 | 0 |
| 30 Jun 20 | 2,237 | 79 | 265 | 0 |
| 31 Mar 20 | 2,608 | 102 | 267 | 0 |
| 31 Dec 19 | 3,220 | 127 | 264 | 0 |
| 30 Sep 19 | 3,970 | 188 | 272 | 0 |
| 30 Jun 19 | 4,098 | 195 | 241 | 0 |
| 31 Mar 19 | 3,779 | 178 | 236 | 0 |
| 31 Dec 18 | 2,997 | 146 | 204 | 0 |
| 30 Sep 18 | 2,697 | 119 | 194 | 0 |
| 30 Jun 18 | 2,315 | 85 | 186 | 0 |
| 31 Mar 18 | 2,130 | 65 | 179 | 0 |
| 31 Dec 17 | 2,148 | 72 | 179 | 0 |
| 30 Jun 17 | 2,034 | 90 | 180 | 0 |
| 31 Mar 17 | 2,159 | 129 | 171 | 0 |
Quality Earnings: SMSLIFE has high quality earnings.
Growing Profit Margin: SMSLIFE's current net profit margins (6.9%) are higher than last year (1.5%).
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: SMSLIFE's earnings have grown by 0.3% per year over the past 5 years.
Accelerating Growth: SMSLIFE's earnings growth over the past year (377%) exceeds its 5-year average (0.3% per year).
Earnings vs Industry: SMSLIFE earnings growth over the past year (377%) exceeded the Pharmaceuticals industry 20.5%.
Return on Equity
High ROE: SMSLIFE's Return on Equity (10.3%) is considered low.
Return on Assets
Return on Capital Employed
Discover strong past performing companies
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/01/10 21:34 |
| End of Day Share Price | 2025/01/10 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2024/03/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
SMS Lifesciences India Limited is covered by 1 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Kameswari V. S. Chavali | FirstCall Research |